These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36613911)

  • 1. Heavy Metals and Essential Metals Are Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease.
    Babić Leko M; Mihelčić M; Jurasović J; Nikolac Perković M; Španić E; Sekovanić A; Orct T; Zubčić K; Langer Horvat L; Pleić N; Kiđemet-Piskač S; Vogrinc Ž; Pivac N; Diana A; Borovečki F; Hof PR; Šimić G
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid/plasma quotients of essential and non-essential metals in patients with Alzheimer's disease.
    Gerhardsson L; Lundh T; Londos E; Minthon L
    J Neural Transm (Vienna); 2011 Jun; 118(6):957-62. PubMed ID: 21373763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Metal Levels between Postmortem Brain and Ventricular Fluid in Alzheimer's Disease and Nondemented Elderly Controls.
    Szabo ST; Harry GJ; Hayden KM; Szabo DT; Birnbaum L
    Toxicol Sci; 2016 Apr; 150(2):292-300. PubMed ID: 26721301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Ng KP; Therriault J; Kang MS; Pascoal TA; Rosa-Neto P; Gauthier S;
    Transl Neurodegener; 2018; 7():23. PubMed ID: 30311914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison and Risk Assessment of Macroelements and Trace Metals in Commercial Teas from Different Regions of China.
    Li F; Jing M; Ma F; Wang W; Li M
    Biol Trace Elem Res; 2023 Mar; 201(3):1503-1519. PubMed ID: 35467266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
    Deming Y; Black K; Carrell D; Cai Y; Del-Aguila JL; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Bertelsen S; Huang KL; Sutphen CL; Tarawneh R; Fagan AM; Holtzman DM; Morris JC; Goate AM; Dougherty JD; Cruchaga C
    BMC Neurol; 2016 Nov; 16(1):217. PubMed ID: 27832767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the relationship between the blood concentration of several metals, macro- and micronutrients and endocrine disorders associated with male aging.
    Rotter I; Kosik-Bogacka DI; Dołęgowska B; Safranow K; Kuczyńska M; Laszczyńska M
    Environ Geochem Health; 2016 Jun; 38(3):749-61. PubMed ID: 26254889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study.
    Dage JL; Eloyan A; Thangarajah M; Hammers DB; Fagan AM; Gray JD; Schindler SE; Snoddy C; Nudelman KNH; Faber KM; Foroud T; Aisen P; Griffin P; Grinberg LT; Iaccarino L; Kirby K; Kramer J; Koeppe R; Kukull WA; La Joie R; Mundada NS; Murray ME; Rumbaugh M; Soleimani-Meigooni DN; Toga AW; Touroutoglou A; Vemuri P; Atri A; Beckett LA; Day GS; Graff-Radford NR; Duara R; Honig LS; Jones DT; Masdeu JC; Mendez MF; Musiek E; Onyike CU; Riddle M; Rogalski E; Salloway S; Sha SJ; Turner RS; Wingo TS; Wolk DA; Womack KB; Carrillo MC; Dickerson BC; Rabinovici GD; Apostolova LG;
    Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S115-S125. PubMed ID: 37491668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
    Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
    J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
    Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
    Antonell A; Mansilla A; Rami L; Lladó A; Iranzo A; Olives J; Balasa M; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2014; 42(3):901-8. PubMed ID: 25024322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.
    Lleó A; Alcolea D; Martínez-Lage P; Scheltens P; Parnetti L; Poirier J; Simonsen AH; Verbeek MM; Rosa-Neto P; Slot RER; Tainta M; Izaguirre A; Reijs BLR; Farotti L; Tsolaki M; Vandenbergue R; Freund-Levi Y; Verhey FRJ; Clarimón J; Fortea J; Frolich L; Santana I; Molinuevo JL; Lehmann S; Visser PJ; Teunissen CE; Zetterberg H; Blennow K
    Alzheimers Dement; 2019 Jun; 15(6):742-753. PubMed ID: 30967340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
    Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
    Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Lundh T; Minthon L; Londos E
    Dement Geriatr Cogn Disord; 2008; 25(6):508-15. PubMed ID: 18463412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.